Metastatic colorectal cancers, for example, show a response rate of only 5–10% to BRAF-inhibitors (8, 14, 31), which has been suggested to be attributed to a higher signaling through EGFR in response to BRAF-inhibitors (32, 33). This evidence concerns the gene EGFR and colorectal cancer.